And caused by high staff costs with no hint why this has increased by 50% this quarter, and last quarter it has already increased by 50%, this can't all be on sales rep??? That is too much for them. These better bring in significant revenue and/or just once-off start-up cost for revenue increase.
I see the worst case is to start again, sell all their commercial products/assets, do a massive staff cut and start again as bio-stock startup with all their focused turned to IMMU to speed the development, using those capitals obtain from the sale as start-up cost, their current MC is already the value of a start-up bio-tech company right now.
Ann: Preliminary Final Report for period to 31 December 2018, page-14
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.09 |
Change
-0.210(1.37%) |
Mkt cap ! $318.9M | |||
| Open | High | Low | Value | Volume |
| $15.10 | $15.38 | $15.02 | $55.26K | 3.65K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 98 | $15.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.57 | 779 | 1 |
View Market Depth
| Last trade - 16.10pm 20/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |